Previous 10 | Next 10 |
home / stock / nvs / nvs articles
In a move outlined in his upcoming State of the Union address, President Joe Biden is pushing for an increase in the number of prescripti...
Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Ph...
As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenom...
Monday, Roche Holdings AG (OTC:RHHBY) announced data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal ...
Tuesday, Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y ...
JP Morgan assumed coverage on BeiGene Ltd (NASDAQ:BGNE), highlighting the potential upside and emphasizing that the recent pullback ...
Monday, Novartis AG (NYSE:NVS) made a voluntary public takeover offer to acquire MorphoSys AG (NASDAQ:MOR) for ?...
MorphoSys AG (NASDAQ:MOR) shares are trading higher Monday following a report suggesting Novartis AG (NYSE:NVS) is in talks to acquire the company....
Under the Inflation Reduction Act, Medicare is poised to send initial offers to manufacturers of the first ten drugs chosen for negotiation, challe...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 13:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for NVS on July 12, 2024 11:58AM ET. The previous analyst recommendation was Equal-Weight. NVS was trading at $111.855 at issue of the analyst recommendation. The overall analyst consensus :...
2024-07-09 01:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...